Regulators in the EU, China, and Japan have started reviews of GSK ... drug for severe asthma that can be given just twice a year. The EMA and counterparts in China and Japan are assessing the ...
“Comparative studies with other AEDs are needed to show how this drug fits in with those already available.” For GSK, success for retigabine might also help offset the anticipated loss of ...
By 1988, it was the world’s best selling drug as patients reported benefits for conditions such as heartburn, ulcers and acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback